Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunoglobulins capable of characterizing curative effect on ITP and application of immunoglobulins in preparing regent for detecting ITP

A technology of immunoglobulin and myosin, applied in the field of biomarkers, can solve the problems of cumbersome operation, time-consuming and laborious, etc., and achieve the effect of avoiding complicated and diagnostic procedures

Active Publication Date: 2019-09-17
内蒙古民族大学附属医院
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to routine blood tests, it is necessary to check platelet count, observe platelet morphology, procoagulant time, clot contraction time, platelet surface-associated immunoglobulin (PAIg) test, anti-human immunoglobulin test, complement test, capillary fragility Tests, bone marrow examination, etc., the operation is cumbersome, time-consuming and laborious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunoglobulins capable of characterizing curative effect on ITP and application of immunoglobulins in preparing regent for detecting ITP
  • Immunoglobulins capable of characterizing curative effect on ITP and application of immunoglobulins in preparing regent for detecting ITP
  • Immunoglobulins capable of characterizing curative effect on ITP and application of immunoglobulins in preparing regent for detecting ITP

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The inventors collected serum samples from normal control group, ITP patients before treatment and ITP patients' effective treatment group. As shown in the following table:

[0021] Table 1. Gender and age of ITP patients

[0022]

[0023] Note: There is no statistical difference between the two groups in gender and age, p>0.05;

[0024] First, patients must meet the following criteria for inclusion:

[0025] 1. Patients with chronic immune thrombocytopenia were clearly diagnosed by bone puncture;

[0026] 2. Exclude thrombocytopenia caused by other secondary factors;

[0027] 3. Platelet count > 10*10^9 / L; no obvious bleeding tendency;

[0028] 4. Patients without hepatic and renal insufficiency;

[0029] 5. Age > 18 years old.

[0030] Secondly, the criteria for treating this group of patients as effective include:

[0031] 1. Thrombocytopenia returned to normal or increased by 30*10^9 / L compared with before treatment;

[0032] 2. The platelet count did not...

Embodiment 2

[0039] On the basis of the above examples, this example: Protein data analysis identified that the content of two proteins, MRIgHV and IGHGγ3-like in the variable region of the myosin-reactive immunoglobulin heavy chain, was abnormally expressed in the ITP patient group, which was higher than that in the normal control group. Significantly down-regulated, but can be restored to similar expression levels in the control group after effective treatment. The two proteins were significantly different in the control group, the ITP patient group and the effective treatment group, such as figure 2 shown. The Gene Ontology enrichment analysis of the two proteins showed that the two proteins were mainly involved in endopeptidase activity, immune effector process, immune response, complement activation, protein activation cascade and reporter gene-mediated endocytosis. The results confirmed that these two proteins are highly correlated with the immune response, making them relevant mar...

Embodiment 3

[0041]On the basis of the above examples, this example: protein data analysis found that, along with the changes in the contents of MRIgHV and IGHGγ3-like proteins in each group of samples, there were corresponding changes in other proteins related to immune-related metabolic pathways, such as uniprot login The numbers are: MRIgHV protein family of Q9UL94, Q9UL75, Q9UL85, Q9UL82, Q9UL78, etc. For example, the heavy chain variable region protein of myosin responsive protein, the light chain variable region protein and other subunit proteins that make up the myosin responsive protein all have the same trend of change. Therefore, it can be guessed that these subunits together constitute the Immunoglobulin may be involved in the immune process of ITP. The details are as follows:

[0042] Table 3. Normal people, effective patients before treatment VS effective patients after treatment related protein expression

[0043]

[0044] Note: Only part of the data is shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a myosin-reactive immunoglobulin heavy chain variable region MRIgHV (the uniprot accession number is Q9UL89) and an unknown protein (immunoglobulin heavy constant gamma3-like, IHCGgamma3-like) (the uniprot accession number is Q6N030) as biomarkers for characterizing the curative effect on ITP. It is found that the content of the MRIgHV and IHCGgamma3-like proteins is correlated with ITP. According to the action mechanism of the MRIgHV and IHCGgamma3-like proteins, the two proteins belong to immunoglobulins, have endopeptidase activity and participate in immune responses, complement activation, protein activation cascading and reporter gene-mediated endocytosis; the two proteins are highly correlated with the immune responses and can serve as the markers for ITP diagnosis.

Description

technical field [0001] The present invention relates to biomarkers, in particular, to the application of myosin-responsive immunoglobulin heavy chain variable region and immunoglobulin heavy chain constant region γ3 analogue two proteins as biomarkers for ITP curative effect evaluation . Background technique [0002] Immune thrombocytopenia (Immune thrombocytopenia, ITP) is an autoimmune bleeding disorder characterized by thrombocytopenia, normal or increased number of bone marrow megakaryocytes with maturation arrest, and the absence of any cause, including exogenous or secondary factors It is the most common clinical thrombocytopenic disease. It is currently recognized that the pathogenesis is related to the abnormal function of humoral immunity and cellular immunity, that is, due to the combination of autoantibodies in the patient's body and platelets, the sensitized platelets are excessively destroyed by the mononuclear macrophage system. In addition to the humoral imm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/00G01N33/53
CPCC07K16/00C07K2317/52C07K2317/56G01N33/53G01N2800/222
Inventor 布仁巴图王双连乌日图那顺龚翠琴哈申高娃额尔敦都楞白海花王彦博
Owner 内蒙古民族大学附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com